Jazz Pharmaceuticals (JAZZ) Change in Account Payables (2010 - 2026)

Jazz Pharmaceuticals' Change in Account Payables history runs 17 years deep, the most recent figure standing at -$21.4 million for Q1 2026.

• On a quarterly basis, Change in Account Payables fell 212.04% year-over-year to -$21.4 million in Q1 2026; TTM through Mar 2026 was -$649000.0, a 103.48% decrease from a year earlier, with the FY2025 full-year figure at $39.9 million, up 298.53% from the prior year.
• Change in Account Payables climbed to -$21.4 million in Q1 2026 per JAZZ's latest filing, from -$29.0 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $62.4 million in Q3 2025 and bottomed at -$29.0 million in Q4 2025.
• The 5-year median for Change in Account Payables is -$8.1 million (2023), against an average of -$190823.5.
• Across the five-year window, Change in Account Payables surged 20493.66% in 2022 and tumbled 1042.52% in 2023, its largest moves.
• Year by year, Change in Account Payables stood at -$15.4 million in 2022, then surged by 47.43% to -$8.1 million in 2023, then jumped by 61.31% to -$3.1 million in 2024, then sank by 824.15% to -$29.0 million in 2025, then rose by 26.14% to -$21.4 million in 2026.
• Per Business Quant, the three latest JAZZ Change in Account Payables figures stand at -$21.4 million (Q1 2026), -$29.0 million (Q4 2025), and $62.4 million (Q3 2025).